baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)
Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen.
Primary Objective:
To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
Secondary Objectives:
To evaluate:
- The change of hemoglobin A1c (HbA1c) from baseline to week 12
- The percentage of patients with HbA1c < 7% at week 12 and week 24
- The FBG and the 7-point self monitoring of blood glucose (SMBG) at baseline, week 12 and week 24
- The daily dose for both insulin glulisine insulin glargine at baseline, week 12 and week 24
- The incidence of symptomatic hypoglycemias
- Adverse events
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
After a two-week run-in period patients will enter a six-month treatment period.
Estimated study duration per patient : 26 weeks (including a 2-week run-in period).
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Algeries、アルジェリア
- Investigational Site Number 01201
-
Algiers、アルジェリア
- Investigational Site Number 01202
-
Algiers、アルジェリア
- Investigational Site Number 01203
-
Algiers、アルジェリア
- Investigational Site Number 01204
-
-
-
-
-
Caba、アルゼンチン
- Investigational Site Number 03201
-
Caba、アルゼンチン
- Investigational Site Number 03202
-
Caba、アルゼンチン
- Investigational Site Number 03203
-
Caba、アルゼンチン
- Investigational Site Number 03204
-
Morón、アルゼンチン
- Investigational Site Number 03205
-
-
-
-
-
Kuwait、クウェート
- Investigational Site Number 01
-
-
-
-
-
Barranquilla、コロンビア
- Investigational Site Number 17003
-
Bogotá、コロンビア
- Investigational Site Number 17004
-
Bogotá、コロンビア
- Investigational Site Number 17005
-
Bogotá、コロンビア
- Investigational Site Number 17007
-
Medellin、コロンビア
- Investigational Site Number 17006
-
-
-
-
-
Riyadh、サウジアラビア、11415
- Investigational Site Number 1
-
-
-
-
-
Sfax、チュニジア
- Investigational Site Number 78805
-
Sfax、チュニジア
- Investigational Site Number 78801
-
Tunis、チュニジア
- Investigational Site Number 78802
-
Tunis、チュニジア、1006
- Investigational Site Number 78803
-
Tunis、チュニジア
- Investigational Site Number 78804
-
-
-
-
-
Curitiba、ブラジル、80540-010
- Investigational Site Number 076-007
-
Distrito Federal、ブラジル、71625-009
- Investigational Site Number 076-003
-
Fortaleza、ブラジル、60430-370
- Investigational Site Number 076-010
-
Marília、ブラジル、17519-101
- Investigational Site Number 076-006
-
Porto Alegre、ブラジル、91350-250
- Investigational Site Number 076-004
-
São Paulo、ブラジル、01244-030
- Investigational Site Number 076-002
-
-
-
-
-
Guadalajara、メキシコ、44600
- Investigational Site Number 48401
-
Guadalajara、メキシコ、44656
- Investigational Site Number 48402
-
Guadalajara、メキシコ、44680
- Investigational Site Number 48404
-
Monterrey、メキシコ、64460
- Investigational Site Number 48403
-
-
-
-
-
Benoni、南アフリカ
- Investigational Site Number 12468
-
Benoni、南アフリカ
- Investigational Site Number 710004
-
Bloemfontein、南アフリカ、9301
- Investigational Site Number 12466
-
Bloemfontein、南アフリカ、9301
- Investigational Site Number 710006
-
Durban、南アフリカ、4091
- Investigational Site Number 710002
-
Durban、南アフリカ、4091
- Investigational Site Number 12464
-
Durban、南アフリカ、4091
- Investigational Site Number 12465
-
Durban、南アフリカ、4091
- Investigational Site Number 710001
-
Port Elizabeth、南アフリカ、6000
- Investigational Site Number 12484
-
Port Elizabeth、南アフリカ、6000
- Investigational Site Number 710003
-
Pretoria、南アフリカ
- Investigational Site Number 12467
-
Pretoria、南アフリカ
- Investigational Site Number 710005
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
Known Type 1 diabetic patients (male or female) treated with any type of insulin regimen, except:
- continuous subcutaneous insulin infusion (CSII, or pump), and
- patients already treated with insulin glargine
- Age: 18-60 years inclusive
- HbA1c: 8% - 10% assessed over the past 6 month
- At least 1 year of continuous insulin treatment
Willingness to accept, and ability to follow:
- a basal bolus regimen (glargine x1 and glulisine x3 per day),
- self-monitoring blood glucose (SMBG)
- a fixed meal plan, or CHO counting
- Signed informed consent obtained prior to any study procedure
Criteria for entry in the treatment period:
- HbA1c 8-10% assessed between week -2 and week 0
- Serum creatinine ≤135 micromol/L in men and ≤110 micromol/L in women
- Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) lower or equal to three times the upper limit of normal
- Pregnancy test negative if women of childbearing potential
Exclusion criteria:
- History of hypersensitivity to insulin glargine and/or insulin glulisine
- Pregnant, breast-feeding or women of childbearing potential not using efficient contraception
- Brittle diabetes
- Known impaired renal function defined as serum creatinine > 135 micromol/L in men and > 110 micromol/L in women at study entry
- Known impaired hepatic function defined as Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal at study entry
- Diabetes ketoacidosis
- History of drug or alcohol abuse
- Psychiatric or mental disease
- Inclusion in another study in the past 6 months or previous inclusion in this study
- Patient unable or unwilling to manage properly the basal bolus regimen
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Insulin glargine + insulin glulisine
Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L). Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL. |
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
他の名前:
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC))
時間枠:between baseline (week 0) and endpoint (week 24)
|
between baseline (week 0) and endpoint (week 24)
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change of HbA1c
時間枠:from baseline to week 12
|
from baseline to week 12
|
|
Percentage of patients with HbA1c < 7%
時間枠:at week 12 and week 24
|
at week 12 and week 24
|
|
Fasting Blood Glucose (FBG)
時間枠:at baseline, week 12 and week 24
|
at baseline, week 12 and week 24
|
|
7-point Self Monitoring of Blood Glucose (SMBG)
時間枠:at baseline, week 12 and week 24 (to be performed the week preceding each visit on two consecutive days)
|
at baseline, week 12 and week 24 (to be performed the week preceding each visit on two consecutive days)
|
|
Daily dose for insulin glulisine
時間枠:At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Daily dose for insulin glargine
時間枠:At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Symptomatic hypoglycemias
時間枠:From baseline (week 0) to endpoint (week 24)
|
From baseline (week 0) to endpoint (week 24)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (見積もり)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- LANTU_R_05033
- U1111-1116-3450 (その他の識別子:WHO)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。